Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

M. de Laurentiis

View on Semantic Scholar

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.

F. Ligorio, L. Provenzano, R. Caputo et al. · 0 citations
Review Open access Sep 2026

Decoding Mitophagy in Breast Cancer: Biological Mechanisms, Dual Roles, and Clinical Implications

Mitophagy is a selective form of autophagy, essential to maintain cellular homeostasis by removing damaged and dysfunctional mitochondria. Several lines of evidence suggest that defective mitophagy is associated with various diseases, including breast cancer. Disruption of mitochondrial quality control contributes to t...

Silvia Zunico, Giorgia Pisano, C. Della Bella et al. · 0 citations
Open access Sep 2026

AI-Enhanced PROMs and Drug-Drug Interaction Screening in Advanced Breast Cancer: Protocol of a Prospective Observational Pilot Study

BackgroundIn advanced breast cancer, treatment pathways are becoming increasingly prolonged and complex across different biological subtypes. New systemic and targeted therapies require long-term monitoring and careful personalization according to patient-specific factors that demand increasingly individualized therape...

O. Tinelli, C. von Arx, R. Caputo et al. · 0 citations
Open access Sep 2026

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

Background Real-world data analyses show durable benefits with elacestrant, with or without prior treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). This cohort focused on patients with ER-positive/HER2-negative estrogen receptor 1 (ESR1)-mutated metastatic breast cancer (mBC) treated with elacestrant afte...

G. Curigliano, M. de Laurentiis, N. Harbeck et al. · 0 citations
Review Open access Aug 2026

Natural Products as Modulators of the DNA Damage Response and Oncogenic Signaling in Breast Cancer Therapy

Recently investigated natural compounds with anti-breast cancer activity are discussed, ranging from polyphenols, terpenoids, alkaloids, sulfur-containing compounds and the emerging plant-derived extracellular vesicles, supporting their potential use in breast cancer therapy.

Maria Cuomo, F. Errichiello, C. Di Meo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.